{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:30:53Z","timestamp":1762921853811,"version":"3.45.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Indonesian Government"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cytogenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic Myeloid Leukemia (CML) is primarily driven by the Philadelphia chromosome, producing the BCR::ABL1 fusion protein. Although imatinib significantly improved CML outcomes, resistance remains a key challenge. Resistance often leads to cytogenetic abnormalities (ACAs), indicating poor disease prognosis. This is the first study that investigates genetic profiles in imatinib-resistant Indonesian CML patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>The study included adult chronic-phase CML patients who met the criteria of treatment failure under the treatment of imatinib. Peripheral blood samples and bone marrow samples were collected and then processed for cytogenetic examination following the International System of Human Cytogenetic Nomenclature (ISCN) guidelines. BCR::ABL1 transcript levels were measured using Quantitative Real-Time PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Out of 27 CML patients, the mean age was 39.15 years, with a male-to-female ratio of 1:1.5. The mean BCR::ABL1 international scale (IS) value was 37.20\u2009\u00b1\u20094.56, and patients on tyrosine kinase inhibitor (TKI) therapy had a median treatment duration of 80 months. Cytogenetic analysis showed Philadelphia chromosome (Ph) positivity in 11.11% of peripheral blood and 34.78% of bone marrow samples, with Ph negativity in 25.93% and 17.93%, respectively. Peripheral blood abnormalities included trisomy 8 (11.11%), additional Ph (7.41%), trisomy 19 (3.70%), and complex karyotypes (14.81%), while bone marrow abnormalities included trisomy 8 (13.04%), additional Ph (8.69%), trisomy 21 (4.35%), monosomy 7\/7q- (8.70%), and complex karyotypes (43.45%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cytogenetic anomalies such as trisomy 8, trisomy 19, and complex karyotypes may contribute to TKI resistance. Further study is needed to understand additional abnormalities observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13039-025-00737-0","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:26:47Z","timestamp":1762921607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytogenetic profile of chronic myeloid leukaemia patients resistant to imatinib at tertiary level in Indonesia"],"prefix":"10.1186","volume":"18","author":[{"given":"Ikhwan","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melva","family":"Louisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elly Yanah","family":"Arwanih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farida Farah","family":"Adibah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello Mikhael","family":"Kadharusman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Alifian","family":"Remifta Putra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Winston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuli Maulidiya","family":"Shufiyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafida Amalia","family":"Salma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"6","key":"737_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709.","journal-title":"Am J Hematol"},{"key":"737_CR2","unstructured":"Eden RE, Coviello JM. Chronic Myelogenous Leukemia [Internet]. StatPearls Publishing. 2023 Jan [cited 2024 Oct 28]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531459\/"},{"key":"737_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.580759","volume":"10","author":"Q Lin","year":"2020","unstructured":"Lin Q, Mao L, Shao L, Zhu L, Han Q, Zhu H, et al. Global, regional, and national burden of chronic myeloid Leukemia, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Front Oncol. 2020;10:1\u201312. https:\/\/doi.org\/10.3389\/fonc.2020.580759.","journal-title":"Front Oncol"},{"issue":"1","key":"737_CR4","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"737_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.33192\/Smj.2022.63","volume":"74","author":"W Rajabto","year":"2022","unstructured":"Rajabto W, Reksodiputro AH, Rinaldi I, Tadjoedin H, Priantono D, Angkasa YK. Chronic myeloid leukemia (CML) at National referral hospital in Indonesia. Siriraj Med J. 2022;74(8):530\u20136.","journal-title":"Siriraj Med J"},{"issue":"10","key":"737_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"19","key":"737_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers (Basel). 2021;13(19):4820.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"737_CR8","first-page":"114","volume":"15","author":"A Amouei","year":"2021","unstructured":"Amouei A, Daeian N, Khezrnia SS, Mansouri A, Hadjibabaie M. Imatinib efficacy, safety and resistance in Iranian patients with chronic myeloid leukemia: a review of literature. Int J Hematol Oncol Stem Cell Res. 2021;15(2):114\u201331.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"7\u20138","key":"737_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000524284","volume":"45","author":"S Sau\u00dfele","year":"2022","unstructured":"Sau\u00dfele S, Kohlbrenner K, Vogelmann T, Schubert T. Incidence. prevalence, and real-world treatment patterns in chronic myeloid leukemia: results from a population-representative German claims data analysis. Oncol Res Treat. 2022;45(7\u20138):400\u20137.","journal-title":"Oncol Res Treat"},{"issue":"1","key":"737_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7150\/ijbs.86305","volume":"20","author":"J Sun","year":"2024","unstructured":"Sun J, Hu R, Han M, Tan Y, Xie M, Gao S, et al. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci. 2024;20(1):175\u201381.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"737_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"11","key":"737_CR12","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, Cayuela J-M, Deininger M, Fabarius A, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37(11):2150\u201367.","journal-title":"Leukemia"},{"issue":"6","key":"737_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou T, Medeiros LJ, Hu S. Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep. 2018;13(6):435\u201345.","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"737_CR14","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.3324\/haematol.2022.282447","volume":"108","author":"L Kockerols","year":"2023","unstructured":"Kockerols L, Dinmohamed AG, de Jong MM, van Norden Y, Biemond BJ, Zweegman S, et al. High-risk additional cytogenetic aberrations in a Dutch chronic myeloid leukemia chronic phase population-based cohort. Haematologica. 2023;108(11):2922\u20136.","journal-title":"Haematologica"},{"issue":"4","key":"737_CR15","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","volume":"5","author":"RE Clark","year":"2021","unstructured":"Clark RE, Apperley JF, Copland M. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5(4):1102\u20139.","journal-title":"Blood Adv"},{"issue":"B","key":"737_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3889\/oamjms.2020.4259","volume":"8","author":"YH ElNahass","year":"2020","unstructured":"ElNahass YH, Assem MM, Saber MM, Abdalla SK, Mahmoud HK, ElRefaey FA. Prognostic impact of additional chromosomal abnormalities in Egyptian chronic myeloid leukemia patients. Open Access Maced J Med Sci. 2020;8(B):623\u201330.","journal-title":"Open Access Maced J Med Sci"},{"issue":"10","key":"737_CR17","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1038\/s41375-022-01681-3","volume":"36","author":"R Hehlmann","year":"2022","unstructured":"Hehlmann R, Lauseker M, Voskanyan A, Fabarius A, Haferlach C, Hochhaus A, et al. Impact of emerging ACA on survival in chronic myeloid leukemia (CML). Leukemia. 2022;36(10):2544\u20137.","journal-title":"Leukemia"},{"issue":"26","key":"737_CR18","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, M\u00fcller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV. Blood. 2011;118(26):6760\u20138.","journal-title":"Blood"},{"issue":"1","key":"737_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1182\/hematology.2022000329","volume":"2022","author":"C Niederwieser","year":"2022","unstructured":"Niederwieser C, Kr\u00f6ger N. Transplantation in CML in the TKI era: who, when, and how? Hematology. 2022;2022(1):114\u201322.","journal-title":"Hematology"},{"issue":"4","key":"737_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12288-013-0316-6","volume":"30","author":"MM Brahmbhatt","year":"2014","unstructured":"Brahmbhatt MM, Trivedi PJ, Patel DM, Shukla SN, Patel PS. Location of the BCR\/ABL fusion genes on both chromosomes 9 in ph negative young CML patients: an Indian experience. Indian J Hematol Blood Transfus. 2014;30(4):241\u20136.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"737_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cancergencyto.2005.05.010","volume":"163","author":"G Fugazza","year":"2005","unstructured":"Fugazza G, Garuti A, Marchelli S, Miglino M, Bruzzone R, Gatti AM, et al. Masked Philadelphia chromosome due to atypical BCR\/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005;163(2):173\u20135.","journal-title":"Cancer Genet Cytogenet"},{"issue":"18","key":"737_CR22","doi-asserted-by":"publisher","first-page":"29906","DOI":"10.18632\/oncotarget.15369","volume":"8","author":"S Luatti","year":"2017","unstructured":"Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, Soverini S, et al. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. Oncotarget. 2017;8(18):29906\u201313.","journal-title":"Oncotarget"},{"issue":"6","key":"737_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"21","key":"737_CR24","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1182\/blood.V116.21.4471.4471","volume":"116","author":"JN Berman","year":"2010","unstructured":"Berman JN, Greer W, Juskevicius R, Fernandez CV, Bernstein M, Couban S. Significant discrepancy in peripheral blood compared to bone marrow BCR-ABL transcript levels in chronic phase chronic myeloid leukemia (CML). Blood. 2010;116(21):4471\u20134471.","journal-title":"Blood"},{"issue":"6","key":"737_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/gim.2016.50","volume":"18","author":"FM Mikhail","year":"2016","unstructured":"Mikhail FM, Heerema NA, Rao KW, Burnside RD, Cherry AM, Cooley LD. Section E6.1\u20136.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow\u2013acquired chromosomal abnormalities. Genet Med. 2016;18(6):635\u201342.","journal-title":"Genet Med"},{"key":"737_CR26","doi-asserted-by":"publisher","unstructured":"Acar K, Uz B. A chronic myeloid leukemia case with a variant translocation t(11;22)(q23;q11.2): masked Philadelphia or simple variant translocation? Pan Afr Med J. 2018;30:161. https:\/\/doi.org\/10.11604\/pamj.2018.30.161.9318. PMID: 30455790.","DOI":"10.11604\/pamj.2018.30.161.9318"}],"container-title":["Molecular Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13039-025-00737-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13039-025-00737-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13039-025-00737-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:26:49Z","timestamp":1762921609000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularcytogenetics.biomedcentral.com\/articles\/10.1186\/s13039-025-00737-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1186\/s13039-025-00737-0","relation":{},"ISSN":["1755-8166"],"issn-type":[{"value":"1755-8166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Faculty of Medicine, University of Indonesia \u2013 Cipto Mangunkusumo National General Hospital (FKUI-RSCM) under the number KET-1424\/UN2.F1\/ETIK\/PPM.00.02\/2023. All patients participating in the study understood and signed a written informed consent form. This study is also in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics apoproval\u00a0"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}